Article
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2022
Zwierenga Fenneke, van Veggel Bianca, Hendriks Lizza E L, Hiltermann T Jeroen N, Hiddinga Birgitta I, Hijmering Kappelle Lucie B M, Ter Elst Arja, Hashemi Sayed M S, Dingemans Anne-Marie C, van der Leest Cor, de Langen Adrianus J, van den Heuvel Michel M, van der Wekken Anthonie J
Abstract excerpt
INTRODUCTION: Patients with life-threatening advanced non-small cell lung cancer (NSCLC) who harbor an exon 20 deletion and/or insertion mutation (EGFRex20 + ) have limited effective treatment options. The high dose 3rd generation tyrosine kinase inhibitor (TKI) osimertinib shows promising in vitro activity in EGFRex20 + NSCLC tumors. METHODS: The POSITION20 is a single arm phase II, multicenter study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.